Ishikawa J, Maeda T, Kashiwagi H, Yoshida H, Takahashi I, Kawamoto S-I, Yamada M, Kato H, Nishiura T, Tomiyama Y, Matsuzawa Y
Department of Internal Medicine and Molecular Science, Osaka University Medical School, Yamadaoka 2-2, B5, Suita, 565-0871, Osaka, Japan.
Bone Marrow Transplant. 2003 Jun;31(11):1057-9. doi: 10.1038/sj.bmt.1704059.
We report the successful treatment of two acute lympho- blastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those used for the first allo-BMT. The patients relapsed on days 154 and 351 from the initial allo-BMT, respectively. Since conventional reinduction chemotherapy failed, allo-PBSCT was undertaken while the patients were still myelosuppressed immediately after reinduction chemotherapy. To induce and/or enhance GVL effects following allo-PBSCT, we performed rapid tapering of CsA and added DLI. After allo-PBSCT and DLI, the patients maintained their complete remission at 55 and 48 months post allo-PBSCT, respectively. From these findings, allo-PBSCT and DLI may be a useful treatment strategy for acute leukemia relapsing after allo-BMT.